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ABSTRACT
Background: Viral infection of the respiratory tract in patients with asthma is one of the most frequent causes
of exacerbation of asthmatic symptoms. Disodium cromoglycate (DSCG) is a commonly used anti-asthmatic
medicine with many beneficial biochemical and physiological effects. The purpose of this study was to investi-
gate the efficacy of DSCG against colds when used in clinical practice.
Methods: A questionnaire survey to determine the efficacy of DSCG was undertaken in 220 adult patients
with asthma (81 male, 139 female; mean age: 54.1 ± 13.7 years and 60.1 ± 12.7 years, respectively) from April
to September 2004 at the Miyatake Asthma Clinic.
Results: The duration of DSCG inhalation therapy was not less than 5 years in more than half of the patients.
The mean daily DSCG dose at the time of the questionnaire survey was 40 mgday in over 50% of all patients.
After DSCG was added to inhaled corticosteroid (ICS) combination therapy, 56.4% of the patients rated their
condition as “improved”, and 66.4% of the patients felt that the frequency of colds they had caught had de-
creased while DSCG was added to ICS.
Conclusions: DSCG inhalation therapy is a useful additional treatment following ICS to alleviate asthma
symptoms, and to prevent colds in adult patients with asthma.
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INTRODUCTION
Viral infection of the airway is an important risk factor
for triggering an attack or exacerbation of bronchial
asthma.1-3 A significant issue in the management and
treatment of patients with asthma is how to prevent
infection from influenza and other viruses responsi-
ble for colds, especially during the winter season.
DSCG is a drug that has been used for more than 35
years, not only for the control of bronchial asthma,
but also for the management of various other allergy-
based diseases. In addition to previously known ac-
tions, such as mast cell stabilization,4,5 and suppres-
sion of various inflammatory cells,6-11 it has recently
been suggested that DSCG exhibits anti-viral action.
To date, however, no consensus has been reached on
the possible anti-viral properties of DSCG, with some
reports affirming this action12-14 and others contra-
dicting it.15,16 In 2002, we identified and reported the
anti-influenza activity of DSCG at in vivo and in vitro
levels in experimental animals.17
According to the Global Initiative for Asthma
(GINA, 2002 version), DSCG is listed as a Step 2
treatment.18 To date, however, the role of DSCG in
the treatment of adults with bronchial asthma has not
yet been clarified. The present study was undertaken
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Fig. 1 The questionnaire survey was conducted from April 1 to September 30, 
2004. Responses were colected from 476 patients with bronchial asthma who 
were treated with DSCG. As a result, in total, 220 patients were included in the 
analysis.
476 (M/187, F/289)
Completed survey on DSCG
366 (139, 227)
Cases were analyzed
220 (81, 139)
ICS preceding the start of 
DSCG, then ICS plus DSCG
combination therapy
Cases excluded from analysis
＊Less than 20 years of age  ＊DSCG Aerosol-A users
＊Cases of COPD  ＊Periodic clinic visits for less than 1 year 
112 (50, 62) 
Cases were excluded
146 (58, 88) 
Cases of simultaneous 
initiation of DSCG and ICS
combination therapy were 
excluded
in an attempt to clarify the role of DSCG in the treat-
ment of adult patients with asthma by a questionnaire
survey of patients, focusing on the anti-asthmatic effi-
cacy and anti-cold virus effects of DSCG.
METHODS
PATIENTS
A questionnaire survey was conducted for 6 months
between April 1 and September 30, 2004. It involved
outpatients with bronchial asthma who received
DSCG inhalation therapy at the Miyatake Asthma
Clinic in Osaka. Responses were collected from 476
patients (187 men, 289 women). The following pa-
tients were excluded from analysis: (1) patients who
were less than 20 years of age, (2) patients who had
visited the clinic regularly but for less than one year,
(3) patients whose asthma was complicated by
chronic obstructive pulmonary disease, which was
classified more than Stage I by GOLD (the Global In-
itiative for Chronic Obstructive Lung Disease.
NHLBIWHO Workshop Report 2001),19 (4) patients
receiving IntalⓇ Aerosol A therapy, and (5) patients
for whom combination therapy with DSCG and ICS
had only just been initiated (Fig. 1).
The reasons for the exclusion of these patients
from the analysis included the following: (1) many of
the patients who were less than 20 years of age had
received DSCG inhalation therapy for many years,
beginning at their school age; if these patients were
included in the analysis, their impressions of the
therapeutic efficacy during childhood may have con-
founded the survey; (2) to clarify the anti-cold virus
effects of DSCG, patients who had been infected with
a cold viruses during at least one season needed to be
enrolled; (3) to clarify the anti-asthmatic efficacy of
DSCG, only patients with bronchial asthma that satis-
fied the diagnostic standards prepared by the Ameri-
can Thoracic Society were enrolled;20 (4) because a
single inhaled dose of IntalⓇ Aerosol A (1 mg1 puff)
differs greatly from that of the IntalⓇ 20 mg cap-
sules, we enrolled only patients treated with the cap-
sule or with the IntalⓇ nebulizer solution (20 mgam-
poule) for inhalation;and (5) to better illustrate the
anti-asthmatic efficacy of DSCG, patients in whom
ICS and DSCG treatments had been simultaneously
initiated were excluded, because ICS has more potent
anti-asthmatic effects than DSCG (Fig. 1).
In total, 220 patients (81 men and 139 women)
were included in the analysis (mean age: 54.1 ± 13.7
years for men and 60.1 ± 12.7 years for women) (Fig.
1). Forty-nine percent of the patients had other atopic
manifestations: allergic rhinitis, pollinosis, atopic der-
matitis and food allergy were 34%, 23.2%, 6.8%, and
3.6%, respectively. One hundred and forty-three pa-
tients were investigated by a serum IgE-RAST test;
positive results of house dust, mites, mold, Japanese
cedar, rag-weed, timothy, cat, and dog were 40.6%,
42.0%, 8.4%, 45.5%, 12.6%, 22.4%, 18.2%, and 13.3%, re-
spectively. Asthma severity was determined accord-
ing to the 2002 GINA Guidelines,18 and were classi-
fied by Step 2, Step 3, and Step 4;these were 55.4%,
38.2%, and 6.4%, respectively. Some patients were
concomitantly treated with anti-asthmatic medicines,
such as inhaled beta2-adrenoceptor agonists, theo-
phylline, rescue oral glucocorticoids, andor leukot-
riene receptor antagonist when necessary.
Anti-cold Virus Effects of DSCG
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STUDY PROTOCOL
This study is a cross sectional questionnaire based
survey, and thus the same patients serve as chrono-
logical controls. The duration of DSCG inhalation
therapy was not less than 5 years in more than half of
all patients. Therefore, the study was a comparison
between two treatment periods in the same patients:
patients treated with ICS monotherapy without DSCG
and patients treated with ICS after an additional treat-
ment with DSCG. The patients had been individually
confirmed and re-educated with respect to their ad-
herence to the inhalation method recommended and
dosage schedule prescribed for the particular formu-
lation by the physician (Dr. Miyatake) repetitively21
until the time of the questionnaire survey (Survey).
The study was approved by the Miyatake Asthma
Clinic Ethics Committee. The objectives and signifi-
cance of the questionnaire survey were explained by
the physician (Dr. Miyatake) to each patient, and
written informed consent was obtained from the pa-
tients. The questionnaire forms were collected and
immediately checked for completeness and to ensure
the entries were appropriate. This check was made
first by the nurse and then by the same physician for
each patient.
When making a final evaluation of the effectiveness
of DSCG inhalation therapy, patients who answered
“I find the therapy effective and want to continue re-
ceiving it” were assessed as to the degree of allevia-
tion they had found for three symptoms (difficulty
breathing, cough, and sputum) using a visual analog
scale (VAS) in an attempt to objectively evaluate the
patient’s impression of effectiveness. The assessment
using a VAS was repeated 6 months later and a com-
parison of the responses in each VAS was performed
to ensure the accuracy of the assessment.
STATISTICAL ANALYSIS
All results are shown as means ± SD. The two groups
were compared using an unpaired Student’s t-test or a
paired t-test. The comparison of asthma status was
performed with the chi-square test. Differences asso-
ciated with p < 0.05 were considered statistically sig-
nificant.
RESULTS
DURATION OF DSCG INHALATION THERAPY
The duration of DSCG inhalation therapy was more
than 1 year but less than 3 years in 27.3% of all sub-
jects, more than 3 years but less than 5 years in
20.0%, more than 5 years but less than 10 years in
26.4%, and more than 10 years in 26.4%.
TYPE OF DSCG INHALER USED AND FRE-
QUENCY OF PEAK EXPIRATORY FLOW MEAS-
UREMENTS
The SpinhalerⓇ was used by 73.2% of all subjects, the
E-halerⓇ by 21.4%, a nebulizer by 4.1% and two or
more of these types of inhalers by 1.4%. Regular peak
expiratory flow (PEF) monitoring was performed in
43.7% of the patients at the time of the start of DSCG
inhalation therapy (Start) and was performed in 40.5%
at the time of the questionnaire survey (Survey).
DAILY DSCG DOSE
The suggested daily DSCG dose at the Start was 80
mgday in 34.5% of all subjects, 60 mgday in 36.4%,
40 mgday in 27.3%, and 20 mgday in 1.8%. The self
claimed daily DSCG dose reported by the patient at
the time of the Survey was 80 mgday in 7.3%, 60 mg
day in 11.4%, 40 mgday in 56.4%, and 20 mgday in
25.0%. The calculated daily DSCG dose in the medical
record was 80 mgday in 3.6%, 60 mgday in 10.5%,
40 mgday in 67.3%, and 20 mgday in 18.6% of all
subjects at the time of the Survey.
TYPE OF ICS USED WHEN DSCG THERAPY
WAS STARTED
The type of ICS used before the start of DSCG ther-
apy was chlorofluorocarbon beclomethasone
dipropionate (CFC-BDP) in 48.6% of all cases, flutica-
sone propionate (FP) in 30.0%, budesonide (BUD) in
18.6% , and hydrofluoroalkane beclomethasone
dipropionate (HFA-BDP) in 2.7%. The mean ICS dose
at the Start was 1020.7 ± 481.0 mcgday on a CFC-
BDP basis.
THE EFFECTS OF COMBINATION THERAPY
WITH DSCG AND ICS AFTER ICS MONOTHER-
APY
After DSCG plus ICS combination therapy, 56.4% of
all cases rated their condition as “improved”, 33.2% as
“I didn’t notice a change”, 5.9% as “DSCG inhalation
therapy alone is preferable” and 4.5% as “ICS therapy
alone is preferable” (Fig. 2). Reasons given for using
combination DSCG plus ICS therapy in a multiple re-
sponse questionnaire included the following; “using
both makes me feel easier” (63.6%), “my physician
recommended it” (45.0%), “throat discomfort and pain
was alleviated following DSCG inhalation therapy”
(10.0%), and “other” (10% or less) (Fig. 3).
THE FREQUENCY OF COLDS FOLLOWING
DSCG PLUS ICS COMBINATION THERAPY
Answers to the question regarding the frequency of
colds following DSCG plus ICS combination therapy
included the following: “I feel the frequency of colds I
have caught has decreased” (66.4%), “I don’t notice a
change” (13.6%) and “I don’t feel the frequency of
colds I have caught has decreased” (9.5%). Thus,
66.4% of the patients had the impression that periodi-
cal inhalation of DSCG was effective against colds
(Fig. 4). When the anti-cold virus effects of DSCG
was analyzed in relation to the duration of DSCG
treatment, there was no association between the du-
ration of DSCG treatment and the percentage of pa-
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Fig. 2 The efects of adding DSCG to ICS were assessed in 220 patients 
with asthma.
(%)
56.4
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33.2
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Need only ICS
Need only DSCG
Didn’t notice a change
Improved conditions
n ＝ 220
Fig. 3 Reasons given for using a combination DSCG plus ICS therapy were asked in a multiple 
response questionnaire.
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Fig. 4 The frequency of colds folowing DSCG plus ICS combination ther
apy was assessed by 220 patients with asthma.
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tients who had the impression that there was a de-
crease in the frequency of colds they had caught
(Fig. 5).
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Fig. 5 The anti-cold viruses efects of DSCG were analyzed in relation to the duration of 
DSCG treatment. 
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Fig. 6 Reasons for having the impression that there was a decrease in 
the frequency of colds caught given by 220 patients with asthma. 
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REASONS FOR HAVING THE IMPRESSION
THAT THE FREQUENCY OF COLDS CAUGHT
HAD DECREASED
The reasons for having the impression that there was
a decrease in the frequency of colds caught given by
the patients were as follows: “effects of DSCG”
(37.7%), “habitual gargling” (23.2%), “unknown”
(21.8%), “effects of ICS” (15.0%) and “other” (5.5%)
(Fig. 6).
COMPARISON OF CLINICAL CHARACTERIS-
TICS BETWEEN ASTHMATIC PATIENTS WHO
HAD AN IMPRESSION OF A DECREASE IN THE
FREQUENCY OF COLDS THEY CAUGHT (YES
GROUP) AND PATIENTS WHO HAD NO SUCH
IMPRESSION (NO GROUP)
One hundred and forty-seven patients (48 men, 99
women) were in the Yes group and 73 patients (33
men, 40 women) were in the No group. The mean
age of patients at time of the Survey did not differ sig-
nificantly between the Yes group (58.4 ± 13.1 years)
and the No group (56.8 ± 13.9 years). The duration of
asthma also did not differ significantly between the
Yes group (17.0 ± 12.8 years) and the No group
(15.5 ± 10.9 years). In addition, no significant inter-
group difference was seen in the incidence of allergic
complications, in the percentage of drug allergies, in
the percentage of smokers or in the percentage of pa-
tients for whom PEF was recorded (Table 1). Labora-
tory findings such as serum IgE-RIST (IUml), pe-
ripheral eosinophil count (%), and indices of respira-
tory function, i.e., FVC (L), FEV1 (L), 50 (Lsec),
and25 (Lsec) at the time of the Survey did not dif-
fer significantly between the Yes group and the No
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Table 1 Clinical characteristics between the Yes group and No group at the time of the questionnaire survey
p-valueNo groupYes group
73147Number of patients
0.07633/4048/99Sex　M/F
0.39456.8 ± 13.958.4 ± 13.1Age (yrs)
0.36415.5 ± 10.917.0 ± 12.8Asthma duration (yrs)
0.56949.347.6Alergic complications (%)
0.49526.021.1Drug alergy (%)
0.51723.318.6Smokers (%)
0.77447.936.8Monitoring PEF (%)
Yes group: Patients have an impression that the frequency of colds caught has decreased.
No group: Patients have no impression that the frequency of colds caught has decreased.
(Mean ± SD)
Table 2 Clinical characteristics of the Yes Group †
n＝147
p-valueSurveyStart
0.729584.1 ± 638.4412.7 ± 694.4IgE (IU/ml)
0.1686.2 ± 4.97.9 ± 6.6Eosinophil (%)
0.9172.37 ± 0.832.36 ± 0.92FVC (L)
0.0011.75 ± 0.681.59 ± 0.75FEV1 (L) ＊
0.0011.74 ± 0.981.38 ± 0.98V・  50 (L/sec) ＊
0.0370.62 ± 0.350.54 ± 0.42V・  25 (L/sec) ＊
0.001786.4 ± 460.31033.7 ± 490.4 ICS (mcg/day) ＊
†Yes group: Patients have an impression that the frequency of colds caught has decreased.
Start: At the time of the start of DSCG. Survey: At the time of the questionnaire survey.
＊Mean ± SD, statisticaly significant
Table 3 Clinical characteristics of the No Group †
n＝73
p-valueSurveyStart
0.172 841.5 ± 1047.9458.6 ± 710.7IgE (IU/ml)
0.0185.2 ± 4.98.9 ± 7.3Eosinophil (%) ＊
0.0112.48 ± 0.862.65 ± 0.91FVC (L) ＊
0.9871.79 ± 0.671.78 ± 0.73FEV1 (L)
0.1181.72 ± 0.941.56 ± 1.01V・  50 (L/sec)
0.9790.63 ± 0.390.62 ± 0.46V・  25 (L/sec)
0.171900.0 ± 386.9944.5 ± 463.6ICS (mcg/day)
†No group: Patients do not have an impression that the frequency of colds caught has decreased.
Start: At the time of the start of DSCG therapy. Survey: At the time of the questionnaire survey.
＊Mean ± SD, statisticaly significant
group. And the ICS dose (mcgday) also did not dif-
fer significantly in the two groups (Tables 2, 3). On
the other hand, the above-mentioned laboratory find-
ings and the ICS dose were compared at the Start of
DSCG and at the time of the Survey in each group.
The Yes group showed a significant increase from
baseline in FEV1, 50 and 25 levels at the time of
the Survey while the mean ICS dose in this group
was lower at the time of the Survey than at the Start
(Table 2). In the No group, the peripheral eosinophil
count was significantly lower than baseline at the
time of the Survey, but respiratory function and the
mean ICS dose had not improved at the time of the
Survey (Table 3).
Anti-cold Virus Effects of DSCG
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ASSESSMENT OF ALLEVIATION OF ASTH-
MATIC SYMPTOMS (DIFFICULTY BREATHING,
COUGH AND SPUTUM) USING A VAS IN PA-
TIENTS WHO FOUND DSCG EFFECTIVE AND
WANTED TO CONTINUE USE
The mean score of assessments at the time of the
Survey was 76 for difficulty breathing, 70 for cough,
and 67 for sputum. These scores appeared to reflect
improvement in respiratory function. When reas-
sessed 6 months later, the mean score remained al-
most unchanged at 72 for difficulty breathing, 72 for
cough, and 70 for sputum. Thus, the anti-asthmatic ef-
fects of DSCG were stable.
PATIENTS’ FINAL EVALUATION OF THE EFFEC-
TIVENESS OF DSCG INHALATION THERAPY AS
A MEANS OF TREATING ASTHMA
The answers of the patients to their final evaluation of
the effectiveness of DSCG inhalation therapy as a
means of treating asthma were as follows: “I find the
therapy effective and want to continue to use it”
(70.5%), “I find the therapy effective but want to dis-
continue its use” (6.4%), “I cannot make an assess-
ment of the efficacy of the therapy but want to con-
tinue to use it” (21.0%), “I cannot make an assessment
of the efficacy of the therapy and want to discontinue
its use” (1.8%), and “I find the therapy ineffective and
want to discontinue its use” (0.5%). Thus, more than
90% of the patients wished to continue DSCG therapy.
DISCUSSION
DSCG is an anti-asthmatic drug that was discovered
in 1965 by Roger Altounyan.22 In Japan, DSCG has
been used as an inhalational drug for bronchial
asthma for more than thirty-five years. DSCG played
an important role in the treatment of children with
bronchial asthma since the time when the regular use
of DSCG and salbutamol inhalation solution was in-
itially recommended.23 DSCG is listed as an alterna-
tive therapy in the GINA,18 in the British Guidelines
on the Management of Asthma,24 and in the Japanese
guidelines on the management of asthma.25 However,
the clinical effects of DSCG on cold viruses have yet
to be determined. We are managing large numbers of
asthmatic patients in clinical practice, and have the
impression that DSCG has anti-viral properties.13,14
In the present study, 66.4% of the 220 adults with
asthma stated that the frequency of colds they had
caught had decreased (Fig. 4). Of these patients,
37.7% stated that the observed decrease in the fre-
quency of colds caught was attributable to the effects
of DSCG (Fig. 6). Furthermore, the study showed
that DSCG exerted anti-cold virus effects which may
last for 10 or more years (Fig. 5).
According to the findings obtained primarily in vi-
tro, the anti-asthmatic effects of DSCG are known to
be exerted through stabilization of the mast cell
membrane,4,5 suppression of eosinophil activation,9
suppression of accumulation of T lymphocytes and
eosinophils,7,10 suppression of the formation of IL-5
by peripheral mononuclear cells,26 suppression of ex-
citation of the sensory nerve C-fiber,27,28 suppression
of the expression of adhesion molecules (ICAM-1,
VCAM-1),10 and suppression of IgE formation.29,30 In
addition, papers either endorsing12-14 or rejecting15,16
the anti-viral properties of DSCG have been pub-
lished.
We previously reported that DSCG suppressed the
infection of MDCK cells by the influenza virus (A
Aichi268, H3N2; AMemphis171, H3N2) and
markedly suppressed fatal infection by the mouse-
adapted influenza virus (APR834, H1N1).17 As for
the mechanism of suppression of viral infection,
DSCG has a symmetric chromone frame resembling
the flavonoid frame, which is known to non-
specifically adsorb viruses, and spectroscopic stud-
ies31,32 have shown that DSCG assumes a liquid crys-
tal form under certain conditions. These findings sug-
gest that in vivo, DSCG forms a thin membrane on
the cell surface and enters the cells along with the in-
vading virus. It then inhibits a series of virus events
(denucleation, replication and budding) by reducing
the pH and other conditions, such as phosphoryla-
tion, involved in virus proliferation. If DSCG exerts
anti-viral effects via this mechanism, it is expected
that DSCG inhibits viruses outside the cells and
hence will exert effects not only against the influenza
virus but also against other viruses.
In a recently reported study of the effects of DSCG
on acute respiratory syncytial virus (RSV) infection in
a mouse model, RSV proliferation in the lungs was
suppressed and lung inflammation was less severe in
mice transnasally pretreated with DSCG, compared
with saline-treated mice.33 Although a variety of possi-
ble means of anti-viral action have been suggested for
DSCG, the exact mechanism has not yet been identi-
fied.
In the present questionnaire survey, 56.4% of pa-
tients who inhaled DSCG in addition to ICS stated
that inhalation of both ICS and DSCG resulted in bet-
ter control of asthma (Fig. 2). In the final assessment,
70.5% of asthmatic patients stated that the use of
DSCG in combination with ICS was effective and that
they wished to continue this therapy. There was a sta-
tistically significant improvement in respiratory func-
tion and a significant reduction in the mean required
dose of ICS in the Yes group (Table 2). These find-
ings may also endorse the anti-asthmatic efficacy of
DSCG.
As the use of ICS in the management of bronchial
asthma is increasing in Japan, the number of patients
admitted to hospitals has decreased and the number
of deaths from asthma has also decreased to less than
3,500 per year. However, control of asthma symptoms
remains difficult in some patients, despite the use of
ICS in combination with long-acting beta2 stimulants
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or the use of theophylline and leukotriene antago-
nists. When dealing with such cases, the addition of
DSCG inhalation therapy is expected to alleviate
asthma symptoms and respiratory dysfunction and to
stabilize the QOL of patients.34,35
In this study, we showed that DSCG inhalation
therapy with ICS may prevent colds. However, this
study is a questionnaire based and cross sectional
survey. Thus our findings are preliminary and need
to be confirmed by case controlled studies. As for the
anti-viral effects of DSCG, we hope that basic and
clinical studies in vitro and in vivo are resumed at
multiple research facilities and that these studies
yield sufficient data to prove the anti-viral effects of
DSCG from the viewpoint of evidence-based medi-
cine.
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